FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced up to $375 million in synthetic royalty and debt financings with Royalty Pharma and investment funds managed by Pharmakon Advisors, LP, of which $250 million in cash was provided at closing and another $125 million in debt is available.

加利福尼亚州福斯特城（商业新闻短讯）--Geron Corporation（纳斯达克代码：GERN）是一家商业阶段的生物制药公司，旨在通过改变血癌的进程来改变生活，今天宣布与royalty Pharma和Pharmakon Advisors，LP管理的投资基金进行高达3.75亿美元的合成特许权使用费和债务融资，其中2.5亿美元的现金在交割时提供，另外1.25亿美元的债务可用。

The transactions are comprised of a $125 million synthetic royalty with Royalty Pharma and $250 million of committed senior secured debt with investment funds managed by Pharmakon Advisors, LP..

这些交易包括与royalty Pharma的1.25亿美元合成特许权使用费和由Pharmakon Advisors，LP管理的投资基金的2.5亿美元承诺优先担保债务。

“The substantial financial commitment of exceptional long-term partners like Royalty Pharma and Pharmakon Advisors strengthens our cash position and further solidifies our balance sheet, while providing flexibility to invest in our future,” said Michelle Robertson, Geron’s Executive Vice President, Chief Financial Officer.

Geron执行副总裁兼首席财务官米歇尔·罗伯逊（MichelleRobertson）表示：“皇室制药（Royalty Pharma）和Pharmakon Advisors等特殊长期合作伙伴的大量财务承诺加强了我们的现金状况，进一步巩固了我们的资产负债表，同时为我们的未来投资提供了灵活性。”

“We believe that the terms reflect the significant commercial potential of RYTELO. The proceeds are expected to enable us to support the commercial launch of RYTELO in the U.S. and potential launch in the EU, complete our Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis, invest in supply chain redundancy for RYTELO, and our general working capital requirements.”.

“我们认为，这些条款反映了瑞泰洛的巨大商业潜力。预计收益将使我们能够支持瑞泰洛在美国的商业推出和在欧盟的潜在推出，完成我们针对复发/难治性骨髓纤维化的IMpactMF第三阶段试验，投资于瑞泰洛的供应链冗余，以及我们的一般运营资本要求。”

Royalty Pharma has provided $125 million at closing and will receive tiered royalty payments on U.S. net sales of RYTELO, ranging from 7.75% of annual net sales up to $500 million, 3.0% of annual net sales between $500 million and $1.0 billion, and 1.0% of annual net sales over $1 billion. Payments to Royalty Pharma will cease if the aggregate royalties payable through June 30, 2031, reach a multiple of 1.65 its investment, otherwise the royalty payments will continue until Royalty Pharma receives a multiple of 2.0 its investment.

Royalty Pharma在交割时提供了1.25亿美元，并将收到RYTELO美国净销售额的分层版税，从年净销售额的7.75%到5亿美元，占年净销售额的3.0%到5亿美元，占年净销售额的1.0%到10亿美元。如果2031年6月30日之前应付的特许权使用费总额达到其投资的1.65倍，则将停止向特许权使用费制药公司支付特许权使用费，否则特许权使用费将持续支付，直到特许权使用费制药公司收到其投资的2倍。

There are no other royalties payable on RYTELO, which was developed internally and is exclusively owned by Geron..

RYTELO是内部开发的，由Geron独家拥有，没有其他应支付的版税。

“RYTELO is an important therapy for the lower-risk MDS patient population, whom otherwise have limited options, and we look forward to its development in other hematologic malignancy indications. We are delighted to establish this partnership with Geron to help fuel their execution of significant commercial and development opportunities ahead,” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma..

Royalty Pharma创始人兼首席执行官巴勃罗·莱戈雷塔（PabloLegorreta）表示：“RYTELO是低风险MDS患者的一种重要疗法，他们的选择有限，我们期待着它在其他血液系统恶性肿瘤适应症中的发展。我们很高兴与Geron建立这种伙伴关系，以帮助他们实现未来的重大商业和发展机会。”

Investment funds managed by Pharmakon Advisors, LP have committed to a 5-year, senior secured term loan of up to $250 million, of which a first tranche of $125 million has been drawn at closing. A portion of these proceeds were used to fully repay amounts owned under the Company’s existing loan with Hercules Capital, Inc.

Pharmakon Advisors，LP管理的投资基金已承诺提供高达2.5亿美元的5年期高级担保定期贷款，其中第一笔1.25亿美元已于交割时提取。这些收益中的一部分用于全额偿还公司向Hercules Capital，Inc.提供的现有贷款。

and Silicon Valley Bank ($86.5 million), which has been terminated. A second tranche of $75 million can be drawn at Geron’s option, subject to certain limited conditions, and a third tranche of $50 million can be drawn at Geron’s option upon reaching a specified RYTELO revenue milestone, in each case if requested prior to December 31, 2025.

和硅谷银行（8650万美元），该银行已被终止。

The facility contains no scheduled amortization payments, with all outstanding principal due at maturity in 2029, and there are no financial covenants. The loans bear interest at a variable rate per year equal to 5.75% plus the three-month Secured Overnight Financing Rate (SOFR), subject to a SOFR floor of 3.00%..

该授信不包含计划摊销付款，所有未偿还本金将于2029年到期，且无财务约定事项。贷款的年可变利率等于5.75%加上三个月担保隔夜融资利率（SOFR），SOFR下限为3.00%。

“The Geron team is driving commercial success in the U.S. with RYTELO, an innovative first-in-class telomerase inhibitor, and we look forward to supporting the company and management team as they plan for a potential launch in the EU and continue to develop the asset in additional hematologic malignancies,” said Pedro Gonzalez de Cosio, Chief Executive Officer of Pharmakon Advisors, LP..

Pharmakon Advisors，LP首席执行官佩德罗·冈萨雷斯·德科西奥（Pedro Gonzalez de Cosio）表示：“Geron团队凭借创新的一流端粒酶抑制剂RYTELO在美国取得了商业成功，我们期待着为公司和管理团队提供支持，因为他们计划在欧盟进行潜在的推出，并继续开发其他血液系统恶性肿瘤的资产。”

TD Cowen served as financial advisor and Cooley LLP served as legal advisor to Geron. Goodwin Procter and Fenwick & West LLP served as legal advisors to Royalty Pharma and Akin Gump LLP served as legal advisor to Pharmakon Advisors, LP.

TD Cowen担任Geron的财务顾问，Cooley LLP担任法律顾问。Goodwin Procter和Fenwick&West LLP担任Royalty Pharma的法律顾问，Akin Gump LLP担任Pharmakon advisors，LP的法律顾问。

About Geron

关于Geron

Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion dependent anemia.

。我们的一流端粒酶抑制剂RYTELO™（imetelstat）在美国被批准用于治疗某些患有输血依赖性贫血的低风险骨髓增生异常综合征（LR-MDS）的成年患者。

We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to reduce proliferation and induce death of malignant cells.

我们还正在进行imetelstat在JAK抑制剂复发/难治性骨髓纤维化（R/R MF）中的关键3期临床试验，以及其他骨髓恶性血液病的研究。抑制骨髓中恶性干细胞和祖细胞中端粒酶活性的增加，旨在减少恶性细胞的增殖并诱导其死亡。

To learn more, visit www.geron.com or follow us on LinkedIn..

要了解更多信息，请访问www.geron.com或在LinkedIn上关注我们。。

Use of Forward-Looking Statements

前瞻性声明的使用

Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) the expected use of proceeds from the debt and synthetic royalty financings; (ii) projections and expectations regarding the sufficiency of the Company’s financial resources to fund its projected operating requirements, including to support commercial launch of RYTELO in the U.S.

除了本文包含的历史信息外，本新闻稿还包含根据1995年《私人证券诉讼改革法》的“安全港”规定所作的前瞻性声明。投资者应注意，此类声明包括但不限于以下内容：（i）债务收益和综合特许权使用费融资的预期用途；（ii）关于公司财务资源是否足以满足其预计运营要求的预测和预期，包括支持RYTELO在美国的商业推出。

and complete its Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis; (iii) the Company’s plans for the potential launch of RYTELO in the EU, subject to regulatory approval; (iv) the developmental and commercial potential of RYTELO; and (v) other statements that are not historical facts, constitute forward-looking statements.

并完成其复发/难治性骨髓纤维化的3期IMpactMF试验；（iii）公司在欧盟可能推出RYTELO的计划，但须经监管部门批准；（iv）RYTELO的发展和商业潜力；（v）其他非历史事实的陈述，构成前瞻性陈述。

These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether Geron is successful in commercializing RYTELO (imetelstat) for the treatment of certain patients with LR-MDS with transfusion dependent anemia; (b) whether Geron overcomes potential delays and other adverse impacts caused by enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing and regulatory challenges in order to have the financial resources for and meet expected timelines and planned milestones; (c) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (d) whether any .

这些前瞻性陈述涉及风险和不确定性，可能导致实际结果与此类前瞻性陈述中的结果存在重大差异。这些风险和不确定性包括但不限于与以下相关的风险和不确定性：（a）Geron是否成功地将RYTELO（imetelstat）商业化，用于治疗某些患有输血依赖性贫血的LR-MDS患者；（b） Geron是否克服了入学、临床、安全、有效性、技术、科学、知识产权、制造和监管挑战带来的潜在延误和其他不利影响，以便拥有财政资源并满足预期的时间表和计划的里程碑；（c） 监管机构是否允许及时进一步开发imetelstat，或者根本不需要任何临床保留；（d） 是否有。